Shared on 31 Oct 25

Fair value Increased 0.89%

Analysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.

Shared on 17 Oct 25

Fair value Decreased 2.19%

Digital Transformation And Advanced Diagnostics Will Create Enduring Value

The consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.

Shared on 03 Oct 25

Fair value Decreased 1.39%

Digital Transformation And Advanced Diagnostics Will Create Enduring Value

Analysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.

Shared on 07 May 25

Fair value Decreased 14%

Digital Transformation And Advanced Diagnostics Will Create Enduring Value

Shared on 30 Apr 25

Fair value Increased 0.43%

Genomics England Partnership And T-SPOT Automation Will Drive Diagnostics Leadership

AnalystConsensusTarget has increased revenue growth from 5.3% to 6.0% and decreased future PE multiple from 38.3x to 33.2x.

Shared on 23 Apr 25

Fair value Decreased 1.85%